With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

The French biotech’s VLA1553 vaccine has been cleared under the Ixchiq brand for use in people aged 18 and over who are at increased risk of exposure to chikungunya, which causes fever and ...

Valneva (VALN) announced that the European Commission has granted marketing authorization in Europe for Valneva’s single-dose vaccine, Ixchiq, for the prevention of disease caused by the ...

Ixchiq received marketing authorization in Europe for individuals 18 years and older in July 2024. The European Commission will now review the CHMP recommendation, and a decision on the label ...

IXCHIQ ® remains available for purchase in France (mainland and overseas). Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 ...

However, challenges such as the slower-than-expected ramp-up of IXCHIQ and regulatory delays in Brazil were acknowledged. Nevertheless, Valneva’s strategic initiatives and successful financial ...

Significant regulatory progress was made with IXCHIQ, including three additional approvals and ongoing label extension activities. The company expanded market access for IXCHIQ, launching in ...

With this extension, IXCHIQ®, the first vaccine against the ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

IXCHIQ® remains available for purchase in France ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Juan ...